Identifying Treatment Targets for Neuroblastoma in the Era of Precision Medicine
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Therapy".
Deadline for manuscript submissions: 22 October 2024 | Viewed by 114
Special Issue Editor
Special Issue Information
Dear Colleagues,
As you are probably already aware, there have been continued efforts toward developing more diagnostically precise and sensitive methods for detecting and targeting genomic alterations in neuroblastoma. With the increasing application of next-generation sequencing (NGS) and other highly sensitive technologies, the integration of genomics, transcriptomics, and assessment of drug efficacy will soon become the standard of care for the treatment and monitoring of pediatric tumors. The purpose of this Special Issue is to highlight recent advances for detecting targetable and prognostic genomic alterations in neuroblastoma as relevant for initial diagnosis, early relapsed/refractory disease, and determining potential targets for immunotherapy. Several assays are currently being explored, including tumor/normal exome analyses, digital droplet PCR (ddPCR) using cell-free circulating tumor DNA, and RNA-sequencing-based assays to assess differentially expressed cell surface molecules. Collectively, these assays have proven their potential for use in future interventional trials to improve outcomes for this high-risk childhood cancer.
Because of your impressive knowledge and research regarding technological advancements in this area, I am seeking your assistance with providing a status update of the current state and future of diagnostic assays for more targeted therapies in pediatric neuroblastoma. I am pleased to invite you to submit an article on your current clinical or translational research studies related to neuroblastoma, which may be printed in book form if sufficient contributions are received. This Special Issue aims to highlight the various molecular technologies capable of identifying potentially actionable genomic alterations in neuroblastoma that are either in use today or applicable in the foreseeable future. Original research articles and reviews are welcome. Research areas may include (but are not limited to) the following:
- The use of tumor/normal exomes for diagnosis and treatment management;
- Testing drug efficacy for high-risk pediatric cancer patients;
- Identifying alterations specific to relapsed/refractory neuroblastoma;
- Potential immunotherapy targets for treating neuroblastoma;
- Comparing/contrasting methodologies for detecting relevant alterations in neuroblastoma;
- Feasibility of implementing targeted cell-free circulating tumor DNA to detect relapse neuroblastoma;
- Genomic biomarkers as related to disease presentation (ganglioneuroma vs. ganglioneuroblastoma vs. neuroblastoma).
I look forward to receiving your contributions.
Dr. Shalini C. Reshmi
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- neuroblastoma
- treatment
- genomic biomarkers
- diagnosis
